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Abstract
Background: Cerebral amyloid angiopathy (CAA) is characterized by deposition of fibrillar amyloid b (Ab) within
cerebral vessels. It is commonly seen in the elderly and almost universally present in patients with Alzheimer’s
Disease (AD). In both patient populations, CAA is an independent risk factor for lobar hemorrhage, ischemic stroke,
and dementia. To date, definitive diagnosis of CAA requires obtaining pathological tissues via brain biopsy (which
is rarely clinically indicated) or at autopsy. Though amyloid tracers labeled with positron-emitting radioligands such
as [
11C]PIB have shown promise for non-invasive amyloid imaging in AD patients, to date they have been unable
to clarify whether the observed amyloid load represents neuritic plaques versus CAA due in large part to the low
resolution of PET imaging and the almost equal affinity of these tracers for both vascular and parenchymal
amyloid. Therefore, the development of a precise and specific non-invasive technique for diagnosing CAA in live
patients is desired.
Results: We found that the phenoxazine derivative resorufin preferentially bound cerebrovascular amyloid deposits
over neuritic plaques in the aged Tg2576 transgenic mouse model of AD/CAA, whereas the congophilic amyloid
dye methoxy-X34 bound both cerebrovascular amyloid deposits and neuritic plaques. Similarly, resorufin-positive
staining was predominantly noted in fibrillar Ab-laden vessels in postmortem AD brain tissues. Fluorescent labeling
and multi-photon microscopy further revealed that both resorufin- and methoxy-X34-positive staining is colocalized
to the vascular smooth muscle (VSMC) layer of vessel segments that have severe disruption of VSMC arrangement,
a characteristic feature of CAA. Resorufin also selectively visualized vascular amyloid deposits in live Tg2576 mice
when administered topically, though not systemically. Resorufin derivatives with chemical modification at the 7-OH
position of resorufin also displayed a marked preferential binding affinity for CAA, but with enhanced lipid
solubility that indicates their use as a non-invasive imaging tracer for CAA is feasible.
Conclusions: To our knowledge, resorufin analogs are the fist class of amyloid dye that can discriminate between
cerebrovascular and neuritic forms of amyloid. This unique binding selectivity suggests that this class of dye has
great potential as a CAA-specific amyloid tracer that will permit non-invasive detection and quantification of CAA
in live patients.
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Cerebral amyloid angiopathy (CAA) is characterized by
amyloid deposition within the walls of leptomeningeal
and cortical arterioles. Among the several types of amy-
loid proteins causing CAA, amyloid b (Ab) is by far the
most common. Ab comprises several species of 39-43-
residue peptides (including Ab1-40 and Ab1-42)t h a ta r e
produced from amyloid precursor protein (APP) via
sequential proteolytic cleavage by b-a n dg-secretases
[1-3]. Soluble Ab monomers are produced throughout
life; in certain individuals, these aggregate to form inso-
luble amyloid fibrils. This pathological form of Ab is the
major constituent of CAA. It is also the primary compo-
nent of neuritic plaques - one of the pathological hall-
marks of Alzheimer’sd i s e a s e( A D ) .T h ec o m p o s i t i o n
and pathogenesis of vascular vs. parenchymal amyloid
deposits, however, have important differences. For
example, while Ab1-42 is thought to be an important
seed for the formation of both parenchymal plaques and
CAA formation [4,5], higher Ab1-40 levels and increased
Ab1-40/Ab1-42 ratios favor formation of CAA over par-
enchymal plaques in mouse models of AD [6-9].
CAA is primarily a disease of the elderly, with about
one-third of individuals aged 60 years or older demon-
strating CAA upon postmortem histopathological exam-
ination. The incidence of CAA is even higher in patients
with AD since these two conditions share common risk
factors. Indeed, up to 90% of AD patients have histologi-
cal evidence of amyloid deposits within cerebral vessels
[10,11]. Clinically, CAA is a well-recognized cause of
“lobar” hemorrhage in the elderly [12,13]. Several popu-
lation-based autopsy studies indicate that CAA is also
an independent risk factor for ischemic stroke and
dementia [14-18]. To further define the relationship
between CAA and its neurological consequences, and to
effectively examine novel therapeutics directed against
CAA, definitive identification of CAA prior to patient
death is critical. Yet, to date, definitive diagnosis of
CAA is possible only by direct examination of patholo-
gical tissue. Short of obtaining such tissue via brain
biopsy, only “possible” or “probable” diagnosis of CAA
is achievable through use of the Boston Criteria, which
utilize MRI to detect lobar microhemorrhage as an
indirect indicator of CAA[19]. This indirect diagnostic
technique, however, is limited by its inability to quantify
CAA severity and its reliance on cerebral hemorrhage as
a surrogate marker for CAA[19]. Development of a non-
invasive method for selectively and accurately diagnos-
ing and quantifying CAA would therefore be a major
breakthrough for this disease.
Investigation into amyloid-imaging ligands for the
diagnosis of AD and the evaluation of anti-amyloid ther-
apy started more than 10 years ago [20-24]. Fibrillar
amyloid-binding dyes such as Congo red, chrysamine G,
and thioflavins were investigated as ligands for positron
emission tomography (PET) and single photon emission
computed tomography (SPECT) imaging of amyloid
deposits in AD patients. Utilizing radiolabeled forms of
these molecules, however, was not clinically feasible due
to their relative inability to cross the blood-brain barrier
(BBB) and their low binding affinities for Ab aggregates.
Since the mid-1990s, many groups have attempted to
develop CNS-accessible amyloid ligands derived from
those molecules. To date, at least two amyloid tracers -
[
11C]PIB ([
11C]6-OH-BTA-1) and [
18F]florbetapir ([[
18F]
AV-45) - have been well characterized. Derived from
thioflavin-T and styrylpyridine, respectively, both display
favorable amyloid binding profiles, suggesting their great
potential as a non-invasive method for early detection of
AD and evaluation of anti-amyloid therapies in AD
patients [25-32]. However, neither dye is appropriate for
the specific diagnosis and quantification of CAA due to
their lack of selectivity for parenchymal versus cerebro-
vascular Ab deposits as well as the low resolution of
PET imaging.
During our laboratory’s exploration into the effects of
CAA deposits on neurovascular architecture and func-
tion in aged APP transgenic mice, we serendipitously
observed that the fluorescent dye resorufin (7-hydroxy-
3H-phenoxazin-3-one) appeared to selectively bind cere-
bral arterioles bearing congophilic fibrillar amyloid. In
this study, we sought to further characterize this unique
amyloid binding property of resorufin, and also explore
the feasibility of utilizing resorufin and/or its derivatives
for CAA-specific amyloid imaging.
Results
In situ evidence that resorufin preferentially binds CAA in
aged Tg2576 mouse brains
Aged Tg2576 mice develop congophilic Ab aggregates
within neuritic plaques throughout the cortex and hip-
pocampus, as well as within cortical leptomeningeal and
penetrating arteries [6,33-35]. To determine whether
resorufin detects Ab aggregates in situ, fixed brain tis-
sues prepared from aged (12-16 mo) Tg2576 mice were
co-stained with the Congo red derivative methoxy-X34
and resorufin, followed by fluorescent microscopy (Fig-
ure 1). Consistent with previous reports [33,35], we
found that methoxy-X34 visualized both cerebrovascular
Ab deposits and neuritic plaques in aged Tg2576 mice
(Figure 1A). The fluorescent dye resorufin (Ex:5 7 3n m ;
Em: 590 nm), however, was found to strongly bind
CAA-laden cerebral arterioles but not parenchymal
neuritic plaques (Figure 1B). Moreover, resorufin-posi-
tive staining was exactly colocalized to methoxy-X34-
positive staining in CAA-laden vessels (Figure 1C and
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Page 2 of 12Figure 1 Resorufin preferentially binds CAA in aged Tg2576 brain sections. Paraformaldehyde-fixed brain sections prepared from 16-
month-old Tg2576 transgenic mice (Tg) or littermate wild-type mice were co-stained with 1 μM resorufin (Res) and 2 μM methoxy-X34 (X34),
followed by fluorescent microscopy (N = 6-8). Representative images of X34 and resorufin staining in Tg2576 mice (A-C) and wild-type mice (D)
are shown. Resorufin selectively binds CAA-laden arterioles (arrowheads) but not senile plaques (arrows), whereas the Congo red derivative
methoxy-X34 labels both. Both resorufin and methoxy-X34 staining was absent in age-matched WT mice. Scale bars in A-D: 100 μm. CAA loads
(E) and neuritic plaque loads (F) as determined by methoxy-X34 (X34) staining vs. resorufin staining in the motor cortex of Tg2576 mice were
plotted.
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Page 3 of 121E), indicating that resorufin directly interacted with
cerebrovascular Ab aggregates. In contrast, resorufin did
not bind methoxy-X34-positive neuritic plaques (Figure
1C and 1F). Both resorufin and methoxy-X34 reactivity
was absent in age-matched wild-type mice (Figure 1D)
and in young (6-month-old) Tg2576 mice that do not
have fibrillar amyloid deposits (data not shown). These
data clearly and directly indicate that resorufin preferen-
tially binds cerebrovascular Ab aggregates over neuritic
plaques in brain sections of aged Tg2576 mice.
Resorufin-positive staining localizes to areas of disrupted
vascular integrity in CAA-affected vessels in aged Tg2576
mouse brains
To explore whether resorufin-positive amyloid deposits
influence vascular smooth muscle cell (VSMC) architec-
ture, whole brains from aged Tg2576 transgenic mice
and wild-type littermate controls were fixed and subse-
quently stained with resorufin and the VSMC marker
phalloidin-Alexa 488. In line with our previous findings
[35], multi-photon microscopy demonstrated that
VSMCs were arranged closely in parallel in control mice
as well as CAA-free pial arterioles in Tg2576; such ves-
sels (and vessel segments) did not stain with resorufin
(Figure 2). However, resorufin- and methoxy-X34-posi-
tive Ab deposits in cerebral vessels were frequently
noted in cerebral vessels of aged Tg2576 mice. In these
vessels, VSMC arrangement was found to be substan-
tially disrupted - a characteristic feature of CAA.
In situ evidence that resorufin preferentially binds CAA in
human AD brains
We next examined whether resorufin preferentially
binds CAA deposits in human AD brains by immuno-
fluorescent labeling. Paraffin-embedded cortical sections
were incubated with the anti-Ab antibody 3D6 followed
by staining with resorufin (Figure 3). Consistent with
our results in Tg2576 mice (Figure 1), marked resoru-
fin-positive staining was noted in the 3D6-positive cere-
bral arterioles of human AD brains (arrowheads in
Figure 3). In contrast, resorufin did not colocalize to
3D6-positive neuritic plaques. Interestingly, resorufin-
positive staining was occasionally present in the core of
congophilic neuritic plaques (arrows in Figure 3). We
also observed that tissues at more advanced stages of
CAA pathology (i.e., those with greater numbers of
CAA-laden vessels) demonstrated more intense resoru-
fin-positive staining of vessels (data not shown).
In vivo live imaging of CAA amyloid deposits in aged
Tg2576 mice
We observed that intravenous administration of resoru-
fin (up to 50 mg/kg) in aged Tg2576 mice (15 mo, i.e.,
at an age when CAA is highly prevalent) failed to
visualize CAA deposits. Instead, the highly fluorescent
resorufin remained within the lumen of cerebral blood
vessels (data not shown), indicating that resorufin failed
to cross the BBB, probably due to its low lipophilicity
(logPoct). We therefore examined whether resorufin was
able to selectively visualize CAA deposits in live Tg2576
mice utilizing a closed cranial window preparation with
real time imaging-fluorescent microscopy[35]. Topical
application of resorufin (2 μM) onto the brain surface of
aged Tg2576 mice through the cranial window resulted
in intense fluorescent labeling within the walls of the
leptomeningeal arteries (arrowheads in Figure 4A), but
not in neuritic plaques (arrows in Figure 4A). In con-
trast, topical application of methoxy-X04 labeled Ab
aggregates in both cerebral arteries and parenchymal
neuritic plaques (arrowheads and arrows in Figure 4B,
respectively). Higher magnification images revealed that
both resorufin and methoxy-X04 were colocalized to the
vascular smooth muscle cell layer, forming circumferen-
tial bands around the vessel (Figure 4D). In contrast, no
staining was seen following superfusion of resorufin or
methoxy-X04 in age-matched wild-type mice or young
Tg2576 mice (data not shown).
Resorufin derivatives with increased lipophilicity
demonstrate improved binding affinities for CAA
Several authors have postulated that moderate lipophili-
city (logPoct in range of 1-3) is an essential characteristic
of amyloid imaging tracers in order to ensure high
initial brain uptake and rapid clearance from the normal
brain [22,36]. To determine logPoct values of resorufin
analogs, octanol-water partition coefficient was exam-
ined by fluorometric methods. We found that the acidic
compound resorufin had weak lipophilicity (logPoct
0.43), while ethoxy- and benzyloxy-resorufin showed
increased lipophilicity (logPoct values of 1.94 and 2.21,
respectively), indicating more appropriate partition coef-
ficient feasible for amyloid imaging in vivo (Table 1).
We then compared the binding affinities of resorufin
analogs for CAA deposits versus neuritic plaques in
fixed Tg2576 brain tissues utilizing their intrinsic fluor-
escence (Figure 5). Similar to our results with resorufin
(Figure 1), both ethoxy-resorufin and benzyloxy-resoru-
fin preferentially bound CAA-laden vessels but not
neuritic plaques in aged Tg2576 mice (Figure 5A). The
dissociation constants (KD) of resorufin and its deriva-
tives were determined by the saturation binding assay
performed at various concentrations (Table 2). The
binding affinity of resorufin was calculated as 874 ± 177
nM (n = 3) on CAA deposits (Figure 5B), whereas for
neuritic plaques it was > 10,000 nM (Figure 5C). The
binding affinities of ethoxy- and benzyloxy-resorufin for
CAA deposits were significantly higher than that of
resorufin (ethoxy-resorufin: KD 247 ± 135 nM;
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Page 4 of 12Figure 2 Multi-photon imaging reveals colocalization of resorufin and methoxy-X34 in CAA-affected vessels.F i x e dw h o l eb r a i n s
prepared from aged Tg2576 mice were labeled with a vascular smooth muscle cell (VSMC) marker phalloidin-Alexa 488 (green), and amyloid
binding dyes methoxy-X34 (blue) and resorufin (red), followed by imaging by multi-photon microscopy (n = 7). A. Representative fluorescent
images in the same field demonstrate co-localization of resorufin and X34 staining in the leptomeningeal vessels of aged Tg2576 mice. B. Higher
magnification images show that both resorufin and methoxy-X34 are co-localized to the VSMC layer of the vessel segment having severe
disruption of VSMC arrangement - a characteristic feature of CAA. In contrast, both methoxy-X34 and resorufin staining is absent in the vessel
segment with no CAA pathology. Scale bars, in A: 50 μm; in B: 25 μm.
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Page 5 of 12benzyloxy-resorufin: KD 473 ± 82 nM). In contrast to
resorufin analogs, methoxy-X34 bound almost equally to
CAA deposits (KD: 325 ± 39 nM) and to neuritic pla-
ques (KD: 219 ± 86 nM).
Discussion
In the present study, we report three key findings: 1)
that resorufin preferentially binds cerebrovascular Ab
deposits over neuritic plaques in aged Tg2576 mouse
brains as well as in human AD brains; 2) that resorufin
staining colocalizes to a congophilic dye methoxy-X34
in close proximity to dystrophic smooth muscle cells of
CAA-affected vessels; and 3) that resorufin can be modi-
fied to enhance lipophilicity, while preserving marked
selectivity for cerebrovascular Ab deposits. These results
indicate that the phenoxazine derivative resorufin and
its derivatives are, to our knowledge, the first class of
amyloid-imaging dyes that bind CAA in a highly selec-
tive manner. All previously described amyloid imaging
ligands have been shown to bind CAA and neuritic pla-
ques with similar affinity, making it very unlikely that
these dyes could be used to develop PET imaging tra-
cers appropriate for selective and definitive diagnosis of
CAA in live patients. The unique selectivity of resorufin
suggests that this class of dye has great potential as a
CAA-specific amyloid tracer - the development of which
would be a major diagnostic step forward for this fre-
quent but often under-diagnosed condition.
Resorufin has been widely used as a fluorogenic probe
to label bioactive molecules, and as an end-point pro-
duct to measure hydrolytic activities of enzymes includ-
ing peroxidases, cellulases, and aldehyde
dehydrogenases. While examining the effect of CAA
deposits on cerebrovascular oxidative stress, architec-
ture, and function in aged Tg2576 mice, we initially
observed that resorufin generated from Amplex red (a
substrate for peroxidases) directly interacted with CAA
independent of the status of oxidative stress in cerebral
vessels. We characterized the cerebrovascular and par-
enchymal amyloid binding properties of resorufin and
its derivatives ethoxy- and benzyloxy-resorufin. We
found that the strongly fluorescent molecule resorufin
Figure 3 Preferential binding of resorufin to CAA vs. neuritic plaques in human AD brains. Paraffin-embedded cortical brain sections of
human AD patient were subjected to immunofluorescent labeling with anti-Ab antibody (3D6, green) followed by staining with resorufin (red).
Resorufin selectively labeled 3D6-immunoreactive amyloid deposits in arterioles (arrowheads) but only rarely neuritic plaques (arrows).
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Page 6 of 12preferentially bound cerebrovascular Ab aggregates over
neuritic plaques when in situ staining was performed. In
an independent study, Lebouvier et. al. [37] have
reported that resorufin binds to neuritic plaques, neuro-
fibrillary tangles, and CAA in postmortem AD brain
sections. However, the resorufin concentration used in
that study was 2000-fold higher than that used herein (2
mM vs. 1 μM) [37]. Non-selective binding of resorufin
to Ab is expected at a high concentration; importantly,
however, their study did not examine whether lower
concentrations of resorufin detect Ab deposits differen-
tially based on localization in cerebral vessels versus
brain parenchyma. We observed markedly preferential
binding to CAA when staining is performed with low
concentrations of resorufin under stringent conditions
(i.e., washing with PBS then with 50% ethanol-contain-
ing PBS). This preferential binding for CAA cannot be
attributed to artifact during brain tissue processing or
fluorescent labeling since resorufin selectively visualized
CAA deposits when directly applied onto the cortical
surface of live Tg2576 mice (Figure 4).
Two critical conclusions stem from our observations.
First, fluorescent imaging with resorufin can be a highly
useful tool for the selective histopathological evaluation
of CAA. For example, it is currently difficult to quantify
Figure 4 In vivo live imaging of CAA amyloid deposits through closed cranial window. Closed cranial windows were prepared on the
right parietal bone of 16 month-old Tg2576 mice and the congophilic amyloid binding dye methoxy-X04 (X04) was administered (6 mg/kg i.p.).
On the next day, 2 μM resorufin (dissolved in artificial CSF) was superfused over the brain through a closed cranial window for 5 min. After
washing with artificial CSF for 10 min, live fluorescent images of resorufin (red) and X04 (blue) were taken (N = 6). Resorufin selectively labels
amyloid deposits in arterioles (arrowheads) but not neuritic plaques (arrows), whereas methoxy-X04 staining is present in both. Scale bars: 100
μm.
Table 1 Lipophilicity (logPoct) of resorufin analogs
Compound name
alogPoct
Resorufin 0.427 ± 0.036
Ethoxyresorufin 1.942 ± 0.137
Benzyloxyresorufin
Methoxy-X34
2.206 ± 0.104
b0.19
aData represent mean ± S.E.M from three independent experiments.
bData from Klunk et. al. [51].
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Page 7 of 12CAA versus neuritic plaque load using conventional
amyloid dyes (e.g., thioflavin-S or Congo red analogs)
due to their near equal affinity for vascular versus par-
enchymal Ab deposits. By exploiting the preferential
binding properties of resorufin for cerebrovascular
amyloid plaques, this process of CAA quantification can
be performed easily. Second, our data strongly suggest
that the selective binding properties of resorufin can be
exploited to eventually produce a CAA-specific amyloid
tracer.
CAA is a strong and independent risk factor for cere-
bral hemorrhage, ischemic stroke and dementia in AD
and non-AD patient populations [12-18]. Excitingly,
recent preclinical studies have identified several novel
approaches that reduce or even prevent CAA formation
[38-41]. These studies raise the intriguing possibility
that one or more of these CAA-directed therapeutic
strategies might eventually be tested in humans. Unfor-
tunately, such trials would currently be limited by the
Figure 5 In situ binding assay in Tg2576 brain sections. Sixteen month-old Tg2576 mice were perfused with PBS and brains were post-fixed
in 4% paraformaldehyde. Coronal brain sections (40 μm thick) were washed three times with PBS and incubated with various concentrations of
test compounds (4 sections/concentration; 6 concentrations/compound) at room temperature for 30 min. Brain sections were washed twice with
PBS and 50% ethanol in PBS then cover-slipped. A. Representative images of fluorescent labeling with resorufin, ethoxy-resorufin (Ethoxy),
benzyloxy-resorufin (Benzyloxy), and methoxy-X34 (X34) are seen. Note that all resorufin derivatives selectively bind CAA-laden arterioles
(arrowheads), whereas the methoxy-X34 labels both CAA and neuritic plaques (arrows). Scale bar: 100 μm. Fluorescent images of the
sensorimotor cortex were taken and the fluorescent intensity on CAA (B) and neuritic plaques (C) was quantified. Saturation binding curves were
plotted to obtain the binding affinity (KD) values (see Table 2).
Table 2 Amyloid binding affinities (KD) of resorufin
analogs
Compound name On CAA
(nM)
On neuritic
plaques (nM)
Resorufin 874 ± 177 > 10,000
Ethoxyresorufin 247 ± 135 > 10,000
Benzyloxyresorufin
Methoxy-X34
473 ± 82
325 ± 39
> 10,000
219 ± 86
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requires brain biopsy (which is rarely clinically indi-
cated), and “probable” diagnosis of CAA by the Boston
Criteria can be made only in patients who have already
suffered intracerebral hemorrhage. Given that these
bleeds occur less frequently[ 1 9 , 4 2 ]a n da tal a t e rs t a g e
[43] than ischemia, a trial using current diagnostics
would be biased towards inclusion of later-stage CAA
patients. The development of a non-invasive imaging
technique for definitively diagnosing CAA would, in
contrast, permit not only critical observational studies to
better define the natural history of patients with CAA,
but it would also greatly facilitate the organization and
execution of therapeutic clinical trials that could include
CAA patients who experience cerebral ischemia or
dementia, not only hemorrhage.
To date, two chemically unrelated amyloid PET tra-
cers, [
11C]PIB and [
18F]flobetapir, have demonstrated
great promise as a tool for non-invasive amyloid ima-
ging in patients with AD [25-32]. Importantly, however,
these PET tracers are unable to discern whether the
observed amyloid load represents neuritic plaques or
CAA since they label both parenchymal and cerebrovas-
cular amyloid deposits [44-46]. As such, our finding that
resorufin analogs might represent a new class of PET
agent for CAA-selective amyloid imaging is potentially
groundbreaking. However, this must be considered in
the context of well-described selection criteria for an
ideal amyloid imaging PET tracer, including 1) high affi-
nity and selectivity for target Ab aggregates; 2) low
molecular weight (< 400 g/mol); 3) moderate lipophili-
city (logPoct in a range of 1-3); and 4) functional groups
amenable to labeling with a positron-emitting radionu-
cleotide such as
11Co r
18F - resorufin does not yet fulfill
all of these requirements due to its low binding affinity
for CAA (KD: 874 nM) and low lipophilicity (logPoct of
0.43) [22]. Nevertheless, our pilot structure-activity rela-
tionship data show that chemical modification at resoru-
fin’s phenol group is able to improve binding affinity for
CAA and increase lipophilicity while maintaining its
high selectivity for cerebrovascular Ab deposits. These
results suggest that resorufin could serve as a lead com-
pound to design chemical pools and to screen high-affi-
nity, CAA-selective amyloid imaging dyes amenable to
CAA imaging by PET.
Regarding the underlying mechanism by which resoru-
fin analogs preferentially bind CAA over neuritic pla-
ques, several potential explanations exist. One possibility
is that resorufin binds fibrillar Ab at different site(s)
from other amyloid imaging dyes, a hypothesis that is
supported by our observation that resorufin binding to
CAA was not competitively inhibited by the congophilic
dyes methoxy-X34 and methoxy-X04. A second possibi-
lity is that resorufin preferentially recognizes
aggregations of Ab1-40 (the predominant species in
CAA) over Ab1-42 (the predominant species in neuritic
plaques). This hypothesis is supported by our observa-
tion that resorufin detects methoxy-X34-sensitive CAA
from Tg2576 mice and humans (which is composed of
both Ab1-40 and Ab1-42 [6,47]) (Figures 1 and 3), but
does not detect methoxy-X34-sensitive CAA from BRI-
Ab42 transgenic mouse (which is composed almost
exclusively of Ab1-42 [5]) (data not shown). A third pos-
sibility is that resorufin directly interacts with molecules
or proteins that are present in CAA but not in neuritic
plaques. For example, heparan sulfate proteoglycans are
expressed much more highly in cerebrovascular deposits
as compared to neuritic plaques, both in human AD
brains and in HCHWA-D mice carrying the Dutch-type
amyloidosis [48,49]. Further investigation is required to
elucidate the underlying mechanism by which resorufin
preferentially binds CAA over neuritic plaques - the
identification of which will not only shed new light on
CAA pathophysiology but may also lead to novel thera-
peutic targets that could be exploited to help prevent
CAA formation and its neurological consequences.
Conclusions
In summary, to our knowledge, this is the first report
demonstrating that resorufin has high selective affinity
for cerebrovascular Ab aggregates over neuritic plaques
in fixed brain tissues and in live APP transgenic mice.
Resorufin analogs modified at the 7-OH position
demonstrated enhanced lipophilicity while retaining
their high binding affinity for cerebrovascular Ab aggre-
gates. These results suggest that resorufin analogs are
promising potential tracers for CAA-selective imaging,
as opposed to conventional amyloid imaging ligands
that non-selectively bind both CAA deposits and neuri-
tic plaques. Further studies are warranted to determine
whether positron-emitting radioligands such as [
11C]- or
[
18F]-labeled resorufin analogs are feasible for use as
CAA-selective PET or SPECT imaging tracers in experi-
mental mouse models and in humans.
Methods
Animals and materials
All experimental protocols were approved by the Animal
Studies Committee at Washington University. The pro-
duction, genotyping, and background strain (B6/SJL) of
Tg2576 mice used in this study have been described
previously [33,35,50]. Tg2576 mice overexpressing
human APP695 with the familial Swedish AD mutations
at positions 670/671 under control of the hamster prion
protein (PrP) promoter were a generous gift from Dr. K.
Ashe (University of Minnesota, Minneapolis, MN).
Resorufin, ethoxy-resorufin, benzyloxy-resorufin, and
octanol were purchased from Sigma-Aldrich (St. Louis,
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Page 9 of 12MO). Amyloid imaging dyes methoxy-X04 and meth-
oxy-X34 were synthesized as described previously [51].
Fluorescent labeling and quantification of CAA and
neuritic plaque loads in Tg2576 brain sections
Tg2576 and littermate wild-type mice at 12-16 months
of age were anesthetized with isoflurane and transcar-
dially perfused with PBS. Brains were removed, post-
fixed overnight in 4% paraformaldehyde in 0.1 M phos-
phate buffer (pH 7.4) at 4°C, and preserved in 30%
sucrose in 0.1 M phosphate buffer at 4°C. Brains were
sectioned coronally (40 μm) on a freezing sliding micro-
tome as described previously [52]. To label brain sec-
tions with resorufin and methoxy-X34, fixed brain
tissues (4 sections/brain) were washed three times with
PBS and permeabilized by incubating in PBS containing
0.25% Triton-X100 (PBS-T) at room temperature for 30
min. Brain sections were stained with PBS-T containing
1 μM resorufin and 2 μM methoxy-X34 at room tem-
perature for 30 min. Brain sections were washed three
times with PBS and once with 50% ethanol in PBS for 5
min each. After three more PBS washes, brain sections
were mounted on a slide glass and cover-slipped with
Vectashield mounting media (Vector laboratories, Bur-
lingame, CA). Fluorescent staining was visualized using
a Nikon Eclipse ME600 digital video microscopy system
(Nikon Instruments Inc., Melville, NY) and MetaMorph
imaging software (Molecular Devices, Sunnyvale, CA).
Cross-sectional area covered by CAA vessels and par-
enchymal plaques were quantified using ImageJ software
(National Institutes of Health, Bethesda, MD) as pre-
viously described [6].
Triple labeling and multi-photon microscopy
Vascular smooth muscle cells and CAA deposition was
assessed as previously reported [35] with modification.
Paraformaldehyde-fixed who l eb r a i n sw e r ep e r m e a b i -
lized with PBS-T for 20 min at room temperature, and
then incubated with PBS-T containing 1 μMr e s o r u f i n
and 2 μM methoxy-X34 for 30 min at room tempera-
ture. Brains were washed three times with PBS and once
with 50% ethanol in PBS for 5 min each. Brains were
blocked with 2% bovine serum albumin (BSA) in PBS-T
for 30 min, followed by incubation with phalloidin-
Alexa-488 (Invitrogen, Carlsbad, CA) in PBS containing
1% BSA. Fluorescent staining with phalloidin-Alexa488,
resorufin and methoxy-X34 was simultaneously imaged
using a Zeiss LSM 510 META LNO two-photon micro-
scope (Carl Zeiss, Jena, Germany).
Immunofluorescent labeling in human AD brain sections
Paraffin-embedded postmortem brain sections prepared
from patients with AD were provided by the Alzheimer’s
Disease Research Center at Washington University.
Brain tissues (10 μm thick) were deparaffinized with
xylene and rehydrated by incubation with 100-70% etha-
nol and PBS. Brain sections were blocked with buffer
(PBS-BB) containing 0.1% Triton-X 100, 0.2% dry milk
and 1% BSA serum in PBS at room temperature for 1 h.
To label fibrillar amyloid, sections were then incubated
with biotinylated anti-Ab antibody 3D6 (dilution:
1:3000, a generous gift from Dr. David M. Holtzman)
overnight at 4°C. After washing with PBS, sections were
incubated with streptavidin-Alexa 488 (Invitrogen,
Carlsbad, CA), followed by labeling with 1 μM resorufin
as described above. Sections were rinsed with PBS,
cover-slipped and subjected to fluorescent microscopy.
Closed cranial window preparation and live microscopic
imaging
A closed cranial window preparation was performed as
previously reported [35]. Briefly, mice were anesthe-
tized with isoflurane (4% induction, 1.5% mainte-
nance), and a 4-mm diameter craniotomy was
performed with a water-cooled dental drill in the right
parietal bone. Two silastic tubings (ID: 0.3 mm, OD:
0.64 mm; Dow Corning, Midland, MI) were inserted
through the bone wax to permit topical application of
vasodilators. The craniotomy was filled with artificial
cerebrospinal fluid (aCSF) and sealed to the bone with
a microscope coverglass using dental cement. To label
amyloid deposits in the brain, mice were administered
BBB-permeable Congo red derivative methoxy-X04 (6
mg/kg i.p.) as described [35]. Fifteen hours later, mice
were re-anesthetized with isoflurane and a-chloralose,
and ventilated. Fluorescent images were visualized
using a Nikon Eclipse 600 ME digital video micro-
scopy system. To label CAA, aCSF containing 1 μM
resorufin was infused into the cranial window at a rate
of 20 μl/min for 5 min. After washing with aCSF for
10 min, fluorescent resorufin and methoxy-X04 images
were taken.
Determination of lipophilicity (logPoct)
Octanol-water partition coefficients (logPoct) were deter-
mined as described previously with modification [53].
An equal volume (600 μl) of n-octanol (Sigma-Aldrich,
S t .L o u i s ,M O )a n dd i s t i l l e dw a t e rw e r ea d d e dt oa
microcentrifuge tube, followed by an addition of resoru-
fin analogues at a final concentration of 100 μM. The
samples were incubated at room temperature with a
brief vortex every 5 min for 60 minutes. After centrifu-
gation at 2,000 g for 10 min, octanol and water layers
were separately transferred to microcentrifuge tubes.
Concentrations were determined by fluorometry at an
excitation wave length of 530/25 nm and an emission
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tek, Winooski, VT).
List of abbreviations used
AD: Alzheimer’s disease; CAA: cerebral amyloid angiopathy; PET: positron
emission tomography; VSMC: vascular smooth muscle cell; PBS: phosphate-
buffered saline; PBS-T: PBS containing 0.25% Triton-X100; aCSF: artificial
cerebrospinal fluid.
Acknowledgements
The authors thank Guangyi Ling, Min Yoo, Tej Azad and Michael Harries for
their technical assistance, as well as Washington University’s Alzheimer’s
Disease Research Center (ADRC) for human pathological specimens. This
work was supported by grants from the American Health Assistance
Foundation (BHH), Washington University Hope Center and ADRC, and in
part by National Institutes of Health Grant 1RO1NS071011 (GJZ).
Author details
1Department of Neurological Surgery, Washington University School of
Medicine, St. Louis, MO 63110, USA.
2Hope Center for Neurological Disorders,
Washington University School of Medicine, St. Louis, MO 63110, USA.
3Program in Neuroscience, Washington University Division of Biology and
Biomedical Sciences, St. Louis, MO 63110, USA.
4Division of Radiological
Sciences, Washington University School of Medicine, St. Louis, MO 63110,
USA.
5Department of Neurology, Washington University School of Medicine,
St. Louis, MO 63110, USA.
Authors’ contributions
BHH contributed to the general administration and direction of the project,
interpretation of experimental results, and development and writing of the
manuscript. MLZ performed live fluorescent imaging. AKV performed multi-
photon imaging in fixed brain sections and image processing, and writing
of the manuscript. EM contributed to fluorescent imaging, statistical data
analysis, and writing the manuscript. DHK performed the fluorescent ligand
binding assays. JKG performed the CAA load and neuritic plaque load
analyses. WC contributed to the experimental design for structure-activity
relationship of test compounds. RHM contributed to the overall design of
chemical modification and review of data. GJZ contributed to direction of
the project, interpretation of experimental results, and critical reviewing of
the manuscript. All authors read and approved the final manuscript.
Competing interests
BHH, WC, RHM and GJZ have patent applications on the composition,
methods, and use related to resorufin derivatives. The authors declare that
they have no competing interests.
Received: 10 October 2011 Accepted: 22 December 2011
Published: 22 December 2011
References
1. Sisodia SS: Alzheimer’s disease: perspectives for the new millennium. J
Clin Invest 1999, 104:1169-1170.
2. Zhang YW, Xu H: Molecular and Cellular Mechanisms for Alzheimer’s
Disease: Understanding APP Metabolism. Curr Mol Med 2007, 7:687-696.
3. Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev
2001, 81:741-766.
4. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW,
Golde T, McGowan E: Abeta40 inhibits amyloid deposition in vivo. J
Neurosci 2007, 27:627-633.
5. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L,
Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R,
Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Abeta42 is essential
for parenchymal and vascular amyloid deposition in mice. Neuron 2005,
47:191-199.
6. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM,
Holtzman DM: Human apolipoprotein E4 alters the amyloid-beta 40:42
ratio and promotes the formation of cerebral amyloid angiopathy in an
amyloid precursor protein transgenic model. J Neurosci 2005,
25:2803-2810.
7. McCarron MO, Nicoll JA, Stewart J, Cole GM, Yang F, Ironside JW, Mann DM,
Love S, Graham DI: Amyloid beta-protein length and cerebral amyloid
angiopathy-related haemorrhage. Neuroreport 2000, 11:937-940.
8. Domnitz SB, Robbins EM, Hoang AW, Garcia-Alloza M, Hyman BT,
Rebeck GW, Greenberg SM, Bacskai BJ, Frosch MP: Progression of cerebral
amyloid angiopathy in transgenic mouse models of Alzheimer disease. J
Neuropathol Exp Neurol 2005, 64:588-594.
9. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD,
Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-
Schieman ML, Staufenbiel M, Mathews PM, Jucker M: Abeta is targeted to
the vasculature in a mouse model of hereditary cerebral hemorrhage
with amyloidosis. Nat Neurosci 2004, 7:954-960.
10. Maia LF, Mackenzie IR, Feldman HH: Clinical phenotypes of Cerebral
Amyloid Angiopathy. J Neurol Sci 2007, 257:23-30.
11. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO: Cerebral
amyloid angiopathy plays a direct role in the pathogenesis of
Alzheimer’s disease. Pro-CAA position statement. Neurobiol Aging 2004,
25:589-597, discussion 603-584.
12. Vinters HV: Cerebral amyloid angiopathy. A critical review. Stroke 1987,
18:311-324.
13. Greenberg SM: Cerebral amyloid angiopathy and vessel dysfunction.
Cerebrovasc Dis 2002, 13(Suppl 2):42-47.
14. Okazaki H, Reagan TJ, Campbell RJ: Clinicopathologic studies of primary
cerebral amyloid angiopathy. Mayo Clin Proc 1979, 54:22-31.
15. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP: The
clinical spectrum of cerebral amyloid angiopathy: presentations without
lobar hemorrhage. Neurology 1993, 43:2073-2079.
16. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM:
Silent brain infarcts and the risk of dementia and cognitive decline. N
Engl J Med 2003, 348:1215-1222.
17. Itoh Y, Yamada M: Cerebral amyloid angiopathy in the elderly: the
clinicopathological features, pathogenesis, and risk factors. Journal of
medical and dental sciences 1997, 44:11-19.
18. Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N,
Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN: Predominant
deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer’s
disease and hereditary cerebral hemorrhage associated with mutations
in the amyloid precursor protein gene. Am J Pathol 1996, 148:1257-1266.
19. Knudsen KA, Rosand J, Karluk D, Greenberg SM: Clinical diagnosis of
cerebral amyloid angiopathy: validation of the Boston criteria. Neurology
2001, 56:537-539.
20. Lee VM: Amyloid binding ligands as Alzheimer’s disease therapies.
Neurobiol Aging 2002, 23:1039-1042.
21. Suhara T, Higuchi M, Miyoshi M: Neuroimaging in dementia: in vivo
amyloid imaging. The Tohoku journal of experimental medicine 2008,
215:119-124.
22. Henriksen G, Yousefi BH, Drzezga A, Wester HJ: Development and
evaluation of compounds for imaging of beta-amyloid plaque by means
of positron emission tomography. European journal of nuclear medicine
and molecular imaging 2008, 35(Suppl 1):S75-81.
23. Nordberg A: Amyloid imaging in Alzheimer’s disease. Current opinion in
neurology 2007, 20:398-402.
24. Nordberg A: Amyloid plaque imaging in vivo: current achievement and
future prospects. European journal of nuclear medicine and molecular
imaging 2008, 35(Suppl 1):S46-50.
25. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP,
Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML,
Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G,
Mathis CA, Langstrom B: Imaging brain amyloid in Alzheimer’s disease
with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
26. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC,
Rossor MN: Amyloid load and cerebral atrophy in Alzheimer’s disease: an
11C-PIB positron emission tomography study. Ann Neurol 2006,
60:145-147.
27. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, Oikonen V,
Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO: Voxel-based
analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.
Neurology 2006, 1575-1580.
28. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE,
Mathis CA, DeKosky ST, Morris JC: [11C]PIB in a nondemented population:
Han et al. Molecular Neurodegeneration 2011, 6:86
http://www.molecularneurodegeneration.com/content/6/1/86
Page 11 of 12potential antecedent marker of Alzheimer disease. Neurology 2006,
67:446-452.
29. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I,
Wall A, Ringheim A, Langstrom B, Nordberg A: Two-year follow-up of
amyloid deposition in patients with Alzheimer’s disease. Brain 2006,
129:2856-2866.
30. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE,
Kilbourn MR, Skovronsky D, Kung HF: Preclinical properties of 18F-AV-45: a
PET agent for Abeta plaques in the brain. J Nucl Med 2009, 50:1887-1894.
31. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT,
Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF,
Joshi AD, Skovronsky DM, Pontecorvo MJ: In vivo imaging of amyloid
deposition in Alzheimer disease using the radioligand 18F-AV-45
(florbetapir [corrected] F 18). J Nucl Med 2010, 51:913-920.
32. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA,
Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF,
Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH,
Reiman EP, Reiman PEM, Zehntner SP, Skovronsky DM, Group AAS: Use of
florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011,
305:275-283.
33. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F,
Cole G: Correlative memory deficits, Abeta elevation, and amyloid
plaques in transgenic mice. Science 1996, 274:99-102.
34. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG: Age-
dependent changes in brain, CSF, and plasma amyloid (beta) protein in
the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci
2001, 21:372-381.
35. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-
Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ: Cerebrovascular
dysfunction in amyloid precursor protein transgenic mice: contribution
of soluble and insoluble amyloid-beta peptide, partial restoration via
gamma-secretase inhibition. J Neurosci 2008, 28:13542-13550.
36. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT,
Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE: A lipophilic
thioflavin-T derivative for positron emission tomography (PET) imaging
of amyloid in brain. Bioorganic & medicinal chemistry letters 2002,
12:295-298.
37. Lebouvier T, Perruchini C, Panchal M, Potier MC, Duyckaerts C: Cholesterol
in the senile plaque: often mentioned, never seen. Acta neuropathologica
2009, 117:31-34.
38. Hawkes CA, McLaurin J: Selective targeting of perivascular macrophages
for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl
Acad Sci USA 2009, 106:1261-1266.
39. Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM,
Bacskai BJ, Frosch MP: Antibody-mediated clearance of amyloid-beta
peptide from cerebral amyloid angiopathy revealed by quantitative in
vivo imaging. J Neurosci 2007, 27:1973-1980.
40. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK,
Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR,
Gitter BD, May PC, Paul SM, DeMattos RB: Exacerbation of cerebral
amyloid angiopathy-associated microhemorrhage in amyloid precursor
protein transgenic mice by immunotherapy is dependent on antibody
recognition of deposited forms of amyloid beta. J Neurosci 2005,
25:629-636.
41. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G,
Schenk D, Seubert P, Games D: Immunotherapy reduces vascular
amyloid-beta in PDAPP mice. J Neurosci 2008, 28:6787-6793.
42. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE,
Greenberg SM: Silent ischemic infarcts are associated with hemorrhage
burden in cerebral amyloid angiopathy. Neurology 2009, 72:1230-1235.
43. Zipfel GJ, Han H, Ford AL, Lee JM: Cerebral Amyloid Angiopathy.
Progressive Disruption of the Neurovascular Unit. Stroke 2008.
44. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP,
Lo CW, Yao CH, Yen TC, Kung MP: Whole-body biodistribution and brain
PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot
study. Nuclear medicine and biology 2010, 37:497-508.
45. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, Gong SJ,
Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L,
Phan TG, Rowe CC: 11C-PIB binding is increased in patients with cerebral
amyloid angiopathy-related hemorrhage. Neurology 2010, 74:487-493.
46. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC:
Cerebral microhemorrhage and brain beta-amyloid in aging and
Alzheimer disease. Neurology 2011, 77:48-54.
47. Herzig MC, Van Nostrand WE, Jucker M: Mechanism of cerebral beta-
amyloid angiopathy: murine and cellular models. Brain Pathol 2006,
16:40-54.
48. van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den
Heuvel LP, Wesseling P, de Waal RM, Verbeek MM: Heparan sulfate
proteoglycan expression in cerebrovascular amyloid beta deposits in
Alzheimer’s disease and hereditary cerebral hemorrhage with
amyloidosis (Dutch) brains. Acta neuropathologica 2001, 102:604-614.
49. Timmer NM, Schirris TJJ, Bruinsma IB, Otte-Holler I, van Kuppevelt TH, de
Waal RMW, Verbeek MM: Aggregation and cytotoxic properties towards
cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40))
are modulated by sulfate moieties of heparin. Neurosci Res 2010,
66:380-389.
50. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM,
Bales K, Ashe KH, Irizarry MC, Hyman BT: Apolipoprotein E facilitates
neuritic and cerebrovascular plaque formation in an Alzheimer’s disease
model. Ann Neurol 2000, 47:739-747.
51. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP,
Debnath ML, Holt DP, Wang Y, Hyman BT: Imaging Abeta plaques in
living transgenic mice with multiphoton microscopy and methoxy-X04,
a systemically administered Congo red derivative. J Neuropathol Exp
Neurol 2002, 61:797-805.
52. Han BH, D’Costa A, Back SA, Parsadanian M, Patel S, Shah AR, Gidday JM,
Srinivasan A, Deshmukh M, Holtzman DM: BDNF blocks caspase-3
activation in neonatal hypoxia-ischemia. Neurobiol Dis 2000, 7:38-53.
53. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT: Curcumin and dehydrozingerone
derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid
plaque imaging. Journal of medicinal chemistry 2006, 49:6111-6119.
doi:10.1186/1750-1326-6-86
Cite this article as: Han et al.: Resorufin analogs preferentially bind
cerebrovascular amyloid: potential use as imaging ligands for cerebral
amyloid angiopathy. Molecular Neurodegeneration 2011 6:86.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Han et al. Molecular Neurodegeneration 2011, 6:86
http://www.molecularneurodegeneration.com/content/6/1/86
Page 12 of 12